Abstract
Insulin resistance can be regarded to be a cause, a consequence, a sustainer or a marker of the wider neuroendocrine dysfunction within which it occurs. In the final part of our series of reviews, we examine the systemic influences which operate within the metabolic syndrome: the endocrine system, the central nervous system and the immune system. We discuss strategies for integrating the array of information that is being gathered, in particular the need for computer simulation. We also advocate the need to move beyond the linear paradigm of ‘cause and effect’ and use causal networks to think about this system. We also discuss the need to understand the temperospatial organisation of the factors being studied. Finally, we draw together the data, concepts and hypotheses we have reviewed over the course of these four articles.
Keywords: Metabolic syndrome, hypertension, obesity, insulin resistance, epidemiology, cortisol, hypothalamo-pituitaryadrenal axis, insulin, insulin signalling, hyperinsulinemia
Current Vascular Pharmacology
Title: The Etiology of Hypertension in the Metabolic Syndrome Part Four: The Systemic Perspective – The Role of the Neuroendocrine and Immune Systems,and the Challenge of Integration
Volume: 4 Issue: 4
Keywords: Metabolic syndrome, hypertension, obesity, insulin resistance, epidemiology, cortisol, hypothalamo-pituitaryadrenal axis, insulin, insulin signalling, hyperinsulinemia
Abstract: Insulin resistance can be regarded to be a cause, a consequence, a sustainer or a marker of the wider neuroendocrine dysfunction within which it occurs. In the final part of our series of reviews, we examine the systemic influences which operate within the metabolic syndrome: the endocrine system, the central nervous system and the immune system. We discuss strategies for integrating the array of information that is being gathered, in particular the need for computer simulation. We also advocate the need to move beyond the linear paradigm of ‘cause and effect’ and use causal networks to think about this system. We also discuss the need to understand the temperospatial organisation of the factors being studied. Finally, we draw together the data, concepts and hypotheses we have reviewed over the course of these four articles.
Export Options
About this article
Cite this article as:
The Etiology of Hypertension in the Metabolic Syndrome Part Four: The Systemic Perspective – The Role of the Neuroendocrine and Immune Systems,and the Challenge of Integration, Current Vascular Pharmacology 2006; 4 (4) . https://dx.doi.org/10.2174/157016106778521599
DOI https://dx.doi.org/10.2174/157016106778521599 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Polyphenols Effect on Circulating Lipids and Lipoproteins: From Biochemistry to Clinical Evidence
Current Pharmaceutical Design Jean-Baptiste de Sénac’s (1693-1770) Important Work on Cardiology and Valvular Disorders
Current Pharmaceutical Design Cardiovascular Disease in the Rheumatic Diseases: How Systemic Inflammation May Contribute to Atherogenesis
Current Rheumatology Reviews Risk Factors for Development of Heart Failure
Current Cardiology Reviews Severe Coagulation Disorder and Thrombocytopenia Associated with Tigecycline – Case Report and Review of Literature
Current Drug Safety Mitochondrial and Nuclear Genes of Mitochondrial Components in Cancer
Current Genomics Are Carbonic Anhydrase Inhibitors Suitable for Obtaining Antiobesity Drugs ?
Current Pharmaceutical Design Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology Natural Phenolic Compounds as Cardiovascular Therapeutics: Potential Role of their Antiinflammatory Effects
Current Vascular Pharmacology Chemometric Assisted Simultaneous Analysis of Verapamil Hydrochloride, Gliclazide and Simvastatin in Bulk Drug and Fixed Dose Combinatinos (polypill) - A Futuristic Approach
Current Analytical Chemistry Ca2+ Fluxes Involvement in Gene Expression During Cardiac Hypertrophy
Current Vascular Pharmacology Folate Nutrigenetics: A Convergence of Dietary Folate Metabolism, Folic Acid Supplementation, and Folate Antagonist Pharmacogenetics
Drug Metabolism Letters Statins and epilepsy: preclinical studies, clinical trials and statin-anticonvulsant drug interactions
Current Drug Targets Coagulation Factor Xa Inhibition: Biological Background and Rationale
Current Topics in Medicinal Chemistry Centenarian Offspring: A Model for Understanding Longevity
Current Vascular Pharmacology Review of Medicinal Plants Common to Traditional Chinese and Indian Medicines with Relevance to Non-Communicable Diseases
Current Traditional Medicine Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Editorial [Hot Topic:Modifying Cardiovascular Risk Factors: Newer Insights and Preventive Measures (Executive Editor: Aurelio Leone)]
Current Pharmaceutical Design A Role for Endothelin-1 in Peripheral Vascular Disease
Current Vascular Pharmacology Extensive Coronary Calcification: A Clinically Unrecognised Condition
Current Vascular Pharmacology